Onconetix Stock to Reverse Split on Tuesday, September 24th (NASDAQ:ONCO)

Onconetix, Inc. (NASDAQ:ONCO) shares are set to reverse split on Tuesday, September 24th. The 1-40 reverse split was announced on Friday, September 20th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, September 23rd.

Onconetix Price Performance

ONCO traded down $0.03 on Friday, reaching $0.08. The company had a trading volume of 5,121,641 shares, compared to its average volume of 6,247,411. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.10 and a quick ratio of 0.09. Onconetix has a 1 year low of $0.08 and a 1 year high of $0.62. The stock has a 50-day moving average price of $0.14 and a 200-day moving average price of $0.15.

Onconetix (NASDAQ:ONCO) last posted its earnings results on Thursday, August 29th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $0.71 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Onconetix, Inc. (NASDAQ:ONCO) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 306,079 shares of the company’s stock, valued at approximately $51,000. Zurcher Kantonalbank Zurich Cantonalbank owned about 1.37% of Onconetix as of its most recent SEC filing. Hedge funds and other institutional investors own 23.89% of the company’s stock.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.